Transcatheter aortic valve implantation (TAVI) is evolving rapidly as a therapeutic option in patients deemed
to be at high risk for surgical aortic valve replacement. Early outcome and survival of controlled feasibility trials and single-
center experience with TAVI have been previously reported. Valve performance and hemodynamics seem to improve
significantly after TAVI. Long-term outcome up to 3 years have been demonstrated in recent studies. Admittedly, the results
are encouraging with a survival rate at 2 and 3 years ranging from 62 to 74% and from 56 to 61% respectively. The
improvement in hemodynamical and clinical status sustained beyond the 3 years follows up. However, paravalvular leakage
after TAVI remains an important issue in this rapidely evolving field.
Keywords: Aortic valve, TAVI, paravalvular leakage, aortic stenosis, SAVR.
Rights & PermissionsPrintExport